Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010

^{Published on 2011-01-27 05:40:43 - Market Wire}
 

Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 -- BOSTON, Jan. 27, 2011 /PRNewswire/ --

BOSTON, Jan. 27, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union. Solos recently announced the approval of its 2011 recapitalization plan, which allows greater flexibility to utilize the assets of the Company to raise the necessary capital to achieve the aforementioned goals.

"As an innovative HealthCare instrument company, Solos continues to position itself to take advantage of the ever increasing demand of the medical industry," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our portfolio is centered on instruments like the MammoView Breast Endoscopy System that are designed to support a wide range of options from screening and diagnosis, to treatment and management of medical conditions."

The Company expects to post its full unaudited financial results for the three months ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: [ www.solosendoscopy.com ].

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

.

SOURCE Solos Endoscopy, Inc.

RELATED LINKS
[ http://www.solosendoscopy.com ]